相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2021)
Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations
Justine A. Barletta et al.
ENDOCRINE PATHOLOGY (2021)
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4
Vijay G. Bhoj et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
V Subbiah et al.
ANNALS OF ONCOLOGY (2021)
Thyroid cancer incidence trends by histology in 25 countries: a population-based study
Adalberto Miranda-Filho et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
Zohreh Maghsoomi et al.
BMC CANCER (2021)
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Miriam Molina-Arcas et al.
GENES (2021)
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
Aditya Bardia et al.
ONCOLOGIST (2020)
Clinical utility of 177Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity
Rahul V. Parghane et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Targeting RAS in pediatric cancer: is it becoming a reality?
Angelina V. Vaseva et al.
CURRENT OPINION IN PEDIATRICS (2020)
Updates on the Management of Thyroid Cancer
Katherine A. Araque et al.
HORMONE AND METABOLIC RESEARCH (2020)
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin J. Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D
Malcolm J. W. Sim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Update on Fundamental Mechanisms of Thyroid Cancer
Alessandro Prete et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer
Jaydira Del Rivero et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Intracellular RET signaling pathways activated by GDNF
Kumi Kawai et al.
CELL AND TISSUE RESEARCH (2020)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
Michael V. Ortiz et al.
JCO PRECISION ONCOLOGY (2020)
Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy
Erika Grossrubatscher et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Endogenous CD4+ thorn T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations
Joshua R. Veatch et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives
Lucieli Ceolin et al.
ENDOCRINE-RELATED CANCER (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Pharmacological targeting of RAS: Recent success with direct inhibitors
John P. O'Bryan
PHARMACOLOGICAL RESEARCH (2019)
Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing
Raffaele Ciampi et al.
ISCIENCE (2019)
Structure and function of RET in multiple endocrine neoplasia type 2
Ivan Plaza-Menacho
ENDOCRINE-RELATED CANCER (2018)
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
Glenn J. Hanna et al.
CLINICAL CANCER RESEARCH (2018)
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
Meredith K. Chuk et al.
PEDIATRIC BLOOD & CANCER (2018)
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Yongkun Sun et al.
THYROID (2018)
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Ira L. Kraft et al.
CLINICAL CANCER RESEARCH (2018)
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
Alain Ravaud et al.
EUROPEAN JOURNAL OF CANCER (2017)
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
Yasuhiro Ito et al.
THYROID (2017)
Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis
Giorgio Treglia et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2017)
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
M. Schlumberger et al.
ANNALS OF ONCOLOGY (2017)
Kinase Inhibitors in Multitargeted Cancer Therapy
Carla Gentile et al.
CURRENT MEDICINAL CHEMISTRY (2017)
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger et al.
CLINICAL CANCER RESEARCH (2016)
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Qiong J. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Correlative Analyses of RET and RAS Mutations in a Phase 3 Trial of Cabozantinib in Patients With Progressive, Metastatic Medullary Thyroid Cancer
Steven I. Sherman et al.
CANCER (2016)
RAS isoforms and mutations in cancer at a glance
G. Aaron Hobbs et al.
JOURNAL OF CELL SCIENCE (2016)
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Cristina Romei et al.
NATURE REVIEWS ENDOCRINOLOGY (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis
Luciana Audi de Castroneves et al.
THYROID (2016)
RAS proto-oncogene in medullary thyroid carcinoma
Margarida M. Moura et al.
ENDOCRINE-RELATED CANCER (2015)
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
Khanh Do et al.
INVESTIGATIONAL NEW DRUGS (2015)
Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells
Loris Bertazza et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Improving Prospects for Targeting RAS
Harshabad Singh et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Samuel A. Wells et al.
THYROID (2015)
Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
T. C. Schneider et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2015)
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy
Gloria Irene Manfredi et al.
ENDOCRINE (2015)
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma
Marijo Bilusic et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat-and With Which Drug-Those Are the Questions
Maria E. Cabanillas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
RET revisited: expanding the oncogenic portfolio
Lois M. Mulligan
NATURE REVIEWS CANCER (2014)
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
S. M. Lim et al.
ANNALS OF ONCOLOGY (2013)
Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
Elizabeth Fox et al.
CLINICAL CANCER RESEARCH (2013)
Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS
Nishant Agrawal et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Somatic RAS Mutations Occur in a Large Proportion of Sporadic RET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon
A. Boichard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Ning Jin et al.
CLINICAL CANCER RESEARCH (2011)
Mammalian Target of Rapamycin Pathway Activation Is Associated to RET Mutation Status in Medullary Thyroid Carcinoma
Ida Rapa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies
David S. Hong et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:: A 10-year follow-up study
Rossella Elisei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer:: A phase II clinical trial
Fabienne Iten et al.
CLINICAL CANCER RESEARCH (2007)
Current concepts in RET-related genetics, signaling and therapeutics
Ivan Plaza-Menacho et al.
TRENDS IN GENETICS (2006)
Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid
M Papotti et al.
CLINICAL ENDOCRINOLOGY (2001)
分享论文
